Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer

被引：0
|
作者：
Ma, F. [1 ]
Qiu, F. [2 ]
Tong, Z. [3 ]
Wang, J. [4 ]
Shi, Y. [5 ]
Zhang, Y. [2 ,10 ]
Yu, G. [6 ]
Shi, H. [7 ]
Wu, X. [8 ]
Liu, A. [9 ]
Zhang, Y. [2 ,10 ]
Wang, H. [11 ]
Cheng, Y. [12 ]
Yang, H. [13 ]
Li, H. [14 ]
Chang, J. [15 ]
Xing, X. [16 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[3] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Dept Breast Canc Pathol, Tianjin, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Med Oncol, Beijing, Peoples R China
[5] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Med Oncol Dept Breast Canc, Tianjin, Peoples R China
[6] Weifang Peoples Hosp, Med Oncol, Weifang, Peoples R China
[7] Gannan Med Univ, Affiliated Hosp 1, Med Oncol, Ganzhou, Peoples R China
[8] Hubei Canc Hosp, Mammary Ctr, Wuhan, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China
[10] Beijing Hosp, Med Oncol, Beijing, Peoples R China
[11] Nanchang Med Coll, Nanchang Peoples Hosp, Breast Oncol Dept, Nanchang, Jiangxi, Peoples R China
[12] Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China
[13] Hebei Univ, Affiliated Hosp, Med Oncol, Baoding, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Breast Med, Beijing, Peoples R China
[15] Guizhou Med Univ, Affiliated Hosp, Breast Oncol Dept, Guiyang, Guizhou, Peoples R China
[16] Shanghai Escugen Biotechnol Co Ltd, Clin Dev Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.297
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
349MO
引用
收藏
页码：S361 / S362
页数：2
相关论文
共 50 条
  • [21] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC)
    Peacock, N.
    Saleh, M.
    Bendell, J.
    Rose, A. A.
    Dong, Z.
    Siegel, P. M.
    Crowley, E.
    Simantov, R.
    Vahdat, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
    Bardia, Aditya
    Starodub, Alexander
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Chuang, Ellen
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Maliakal, Pius
    Wegener, William A.
    Hamburger, Steven A.
    Ocean, Allyson J.
    Goldenberg, David M.
    Vahdat, Linda T.
    CANCER RESEARCH, 2015, 75
  • [23] The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
    Gail D. Lewis
    Guangmin Li
    Jun Guo
    Shang-Fan Yu
    Carter T. Fields
    Genee Lee
    Donglu Zhang
    Peter S. Dragovich
    Thomas Pillow
    BinQing Wei
    Jack Sadowsky
    Douglas Leipold
    Tim Wilson
    Amrita Kamath
    Michael Mamounas
    M. Violet Lee
    Ola Saad
    Voleak Choeurng
    Alexander Ungewickell
    Sharareh Monemi
    Lisa Crocker
    Kevin Kalinsky
    Shanu Modi
    Kyung Hae Jung
    Erika Hamilton
    Patricia LoRusso
    Ian Krop
    Melissa M. Schutten
    Renee Commerford
    Mark X. Sliwkowski
    Eunpi Cho
    Nature Communications, 15
  • [24] The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
    Lewis, Gail D.
    Li, Guangmin
    Guo, Jun
    Yu, Shang-Fan
    Fields, Carter T.
    Lee, Genee
    Zhang, Donglu
    Dragovich, Peter S.
    Pillow, Thomas
    Wei, Binqing
    Sadowsky, Jack
    Leipold, Douglas
    Wilson, Tim
    Kamath, Amrita
    Mamounas, Michael
    Lee, M. Violet
    Saad, Ola
    Choeurng, Voleak
    Ungewickell, Alexander
    Monemi, Sharareh
    Crocker, Lisa
    Kalinsky, Kevin
    Modi, Shanu
    Jung, Kyung Hae
    Hamilton, Erika
    LoRusso, Patricia
    Krop, Ian
    Schutten, Melissa M.
    Commerford, Renee
    Sliwkowski, Mark X.
    Cho, Eunpi
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [25] A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer
    Andrew H. Ko
    Andrew L. Coveler
    Benjamin L. Schlechter
    Tanios Bekaii-Saab
    Brian M. Wolpin
    Jeffrey W. Clark
    Bruno Bockorny
    Li-Yuan Bai
    Yu-Chin Lin
    Evelyn Chiang
    Peter Langecker
    Shih-Yao Lin
    Investigational New Drugs, 2024, 42 : 221 - 228
  • [26] Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study
    Wang, Jiayu
    Liu, Yunjiang
    Zhang, Qingyuan
    Li, Wei
    Feng, Jifeng
    Wang, Xiaojia
    Fang, Jianmin
    Han, Yiqun
    Xu, Binghe
    CANCER COMMUNICATIONS, 2024, 44 (07) : 833 - 851
  • [27] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
  • [28] A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Vukelja, S.
    Rugo, H.
    Vogel, C.
    Borson, R.
    Tan-Chiu, E.
    Birkner, M.
    Holden, S. N.
    Klencke, B.
    O'Shaughnessy, J.
    Burris, H. A.
    CANCER RESEARCH, 2009, 69 (02) : 71S - 71S
  • [29] BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts
    Yao, Sufei
    Shang, Chengzhang
    An, Gao
    Guo, Chaoshe
    An, W. Frk
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
  • [30] A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).
    Burris, H.
    Saleh, M.
    Bendell, J.
    Hart, L.
    Rose, A. A. N.
    Dong, Z.
    Siegel, P. M.
    Crane, M. F.
    Donovan, D.
    Crowley, E.
    Simantov, R.
    Vahdat, L.
    CANCER RESEARCH, 2009, 69 (24) : 855S - 855S
12345